The Immunogenicity Of Hemophilus Influenzae Type B Polysaccharide-Afeisser/A Meningitidis Group B Outer Membrane Protein Complex Vaccine In Infants And Young Children

Eugene D. Shapiro*, Lisa A. Capobianco, Anne T. Berg, Maryann Q. Zitt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Hemophilus influenzae type b polysaccharide-Afeisseria meningitidis group B outer membrane protein complex vaccine was administered in a single dose to 38 children ages 24-53 mo (group 1) and to 78 children ages 12-23 mo (group 2) and in two doses to 84 children ages 2-11 mo (group 3). The geometric mean concentration of the capsular antibody before and after the vaccine regimen, respectively, were 0.35 ng/ml and 12.59 (ig/ml in group 0.18 ng/ml and 4.79 ng/ml in group 2, and 0.15 ng/ml and 3.80 ig/ml in group 3. After completing the vaccine regimen, concentrations of capsular antibody were >0.15 Hg/ml in 199 (99.5%) of the 200 children and >1.0 ng/ml in 168 (84%) of the children. There were no serious and few minor adverse reactions to the vaccine. This vaccine is immunogenic in infants and young children.

Original languageEnglish (US)
Pages (from-to)1064-1067
Number of pages4
JournalJournal of Infectious Diseases
Volume160
Issue number6
DOIs
StatePublished - Dec 1989

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The Immunogenicity Of Hemophilus Influenzae Type B Polysaccharide-Afeisser/A Meningitidis Group B Outer Membrane Protein Complex Vaccine In Infants And Young Children'. Together they form a unique fingerprint.

Cite this